Patent DE-102006050516-A1 (DE)
Title: New pyrazol-3-one compounds are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful e.g. to treat and/or prophylaxis heart-circulation diseases, heart failure, anemia, chronic kidney diseases and renal failure
Inventor: THEDE KAI
IPC: A61P9/00
Filed: 2006-10-26
Abstract: Pyrazol-3-one compounds (I) and their salts, solvates and solvate of the salts, are new, where (I) excludes 3-methyl-1-(pyridin-2-yl)-4-(1-pyridin-2-yl-3-methyl-1H-pyrazol-5-yl)-2H-3-pyrazolin-5(1H)-one. Pyrazol-3-one compounds of formula (I) and their salts, solvates and solvate of the salts, are new, where (I) excludes 3-methyl-1-(pyridin-2-yl)-4-(1-pyridin-2-yl-3-methyl-1H-pyrazol-5-yl)-2H-3-pyrazolin-5(1H)-one. R 1> : nitrogen containing aryl group of formula (a)-(d); A : C-R 4> or N, where maximum two ring members of A are simultaneously N; E : O, S or N-R 5>; R 2> : nitrogen containing heteroaryl-group of formula (e)-(q); a1, a2 : point of attachment with the dihydropyrazolone ring; G : C-R 6> or N, where maximum two ring members of G are simultaneously N; J : O, S or N-R 7>; L : C-R 8> or N, where maximum two ring members of L are simultaneously N; R 4>, R 6>, R 8> : H, halo, cyano, NO 2, (1-6C)-alkyl (substituted with 1-3 of T), (3-7C)-cycloalkyl, 4-7-membered heterocycloalkyl, phenyl, 5- or 6-membered heteroaryl (where the (hetero)cycloalkyl, phenyl and heteroaryl are substituted with 1-3 of T 1>), -C(=O)-R 9>, -C(=O)-R 1> 0>, -C(=O)-NR 1> 1>R 1> 2>, -O-C(=O) -R 1> 3>, -O-C(=O)-NR 1> 4>R 1> 5>, -NR 1> 6>-C(=O)-R 1> 7>, -NR 1> 8>-C(=O)-OR 1> 9>, -NR 2> 0>-C(=O) -NR 2> 1>R 2> 2>, -NR 2> 3>-SO 2-R 2> 4>, -SO 2-R 2> 5>, -SO 2-NR 2> 6>R 2> 7>, -OR 2> 8>, -SR 2> 9> or -NR 3> 0>R 3> 1>; T : halo, CN, oxo, (3-7C)-cycloalkyl, 4-7-membered heterocycloalkyl, phenyl, 5- or 6-membered heteroaryl, -C(=O)-R 9>, -C(=O)-OR 1> 0>, -C(=O)-NR 1> 1>R 1> 2>, -O-C(=O)-R 1> 3>, -O-C(=O)-NR 1> 4>R 1> 5>, -NR 1> 6>-C(=O)-R 1> 7>, -NR 1> 8>-C(=O)-OR 1> 9>, -NR 2> 0>-C(=O)-NR 2> 1>R 2> 2>, -NR 2> 3>-SO 2-R 2> 4>, -SO 2-R 2> 5>, -SO 2-NR 2> 6>R 2> 7>, -OR 2> 8>, -SR 2> 9> or -NR 3> 0>R 3> 1>, where the cycloalkyl-, heterocycloalkyl-, phenyl- and heteroaryl are substituted by 1-3 of halo, CN, (1-4C)-alkyl, trifluoromethyl, OH, (1-4C)-alkoxy, trifluoromethoxy, oxo, amino, mono-(1-4C)-alkylamino, di-(1-4C)-alkylamino, hydroxycarbonyl and/or (1-4C)-alkoxycarbonyl; T 1> : (1-6C)-alkyl, halo, CN, oxo, -C(=O)-R 9>, -C(=O)-OR 1> 0>, -C(=O)-NR 1> 1>R 1> 2>, -O-C(=O)-R 1> 3>, -O-C(=O)-NR 1> 4>R 1> 5> -NR 1> 6>-C(=O) -R 1> 7>, -NR 1> 8>-C(=O)-OR 1> 9>, -NR 2> 0>-C(=O)-NR 2> 1>R 2> 2>, -NR 2> 3>-SO 2-R 2> 4>, -SO 2-R 2> 5>, -SO 2-NR 2> 6>R 2> 7>, -OR 2> 8>, -SR 2> 9> or -NR 3> 0>R 3> 1>, where the alkyl is substituted with 1-3 of halo, CN, OH, trifluoromethoxy, (1-4C) -alkoxy, amino, mono-(1-4C)-alkylamino, di-(1-4C)-alkylamino, hydroxycarbonyl, (1-4C)-alkoxycarbonyl, (3-7C)-cycloalkyl, 4-7-membered heterocycloalkyl, phenyl or 5- or 6-membered heteroaryl; either R 9>-R 1> 1>, R 1> 3>, R 1> 4>, R 1> 7>, R 1> 9>, R 2> 1>, R 2> 4>, R 2> 5>, R 2> 6>, R 2> 8>-R 3> 0> : H, (1-6C)-alkyl (substituted with 1-3 of halo, cyano, OH, trifluoromethoxy, (1-4C)-alkoxy, amino, mono-(1-4C)-alkylamino, di-(1-4C)-alkylamino, hydroxycarbonyl, (1-4C)-alkoxycarbonyl, (3-7C)-cycloalkyl, 4-7-membered heterocycloalkyl, phenyl or 5- or 6-membered heteroaryl), (where the (hetero)cycloalkyl, phenyl and heteroaryl are substituted with 1-3 of halo, cyano, (1-4C)-alkyl, trifluoromethyl, OH, (1-4C)-alkoxy, trifluoromethoxy, oxo, amino, mono-(1-4C)-alkylamino, di-(1-4C)-alkylamino, hydroxycarbonyl or (1-4C)-alkoxycarbonyl); and R 1> 2>, R 1> 5>, R 1> 6>, R 1> 8>, R 2> 0>, R 2> 2>, R 2> 3>, R 2> 7>, R 3> 1> : H or (1-6C)-alkyl, which is optionally substituted with halo, CN, OH, trifluoromethoxy, (1-4C)-alkoxy, amino, mono-(1-4C)-alkylamino, di-(1-4C)-alkylamino, hydroxycarbonyl or (1-4C)-alkoxycarbonyl; or R 1> 1>R 1> 2>, R 1> 4>R 1> 5>, R 1> 6>R 1> 7>, R 1> 8>R 1> 9>, R 2> 0>R 2> 1>, R 2> 1>R 2> 2>, R 2> 3>R 2> 4>, R 2> 6>R 2> 7>, R 3> 0>R 3> 1> : 5- or 6-membered heterocycloalkyl ring; R 5>, R 7> : H, (1-6C)-alkyl (substituted by T), (3-7C)-cycloalkyl, 4-7-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl (where the (hetero)cycloalkyl, phenyl and heteroaryl are substituted with 1-3 of T 1>); and R 3> : H, (1-6C)-alkyl or (3-7C)-cycloalkyl. Independent claims are included for: (1) preparations of (I); and (2) a medicament comprising (I) and inert, non-toxic auxiliary material. [Image] [Image] [Image] [Image] ACTIVITY : Cardiant; Antianemic; Nephrotropic; Antianginal; Cerebroprotective; Vasotropic; Antiarteriosclerotic; Hypotensive; Dermatological; Antimicrobial; Antiinflammatory; Gastrointestinal-Gen; Antiarthritic; Antirheumatic; Ophthalmological; Antiparkinsonian; Neuroprotective; Nootropic; Analgesic; Vulnerary; Anabolic; Endocrine-Gen; Antidiabetic. MECHANISM OF ACTION : Hypoxia-inducible transcription factor (HIF)-prolyl-4-hydroxylase inhibitor.